FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity
Voltar à Biblioteca de Pesquisa

Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity

May 25, 2026
Share
Pesquisa Emergente

Baseado em pesquisa emergente. Esses achados são promissores, mas requerem validação adicional.

Sobre esta Análise

Este artigo é uma síntese assistida por inteligência artificial de um item noticiário ou lista de ensaios clínicos recentemente publicado. É intenção fornecer uma visão rápida e acessível para a comunidade de pesquisa em peptídeos. Para obter a precisão completa, sempre consulte o

Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity

A new clinical trial aims to test the efficacy and safety of a novel investigational peptide, CS060380, when used alongside semaglutide for treating patients with metabolic dysfunction-associated steatohepatitis (MASH) and obesity. This Phase II study is an exciting development in the world of peptide therapy as it explores potential new avenues to address serious health conditions that are becoming increasingly common.

Background

Metabolic dysfunction-associated steatohepatitis, or MASH, is a condition characterized by fat accumulation in the liver, leading to inflammation and damage. It’s often associated with obesity, type 2 diabetes, and metabolic syndrome. Currently available treatments for MASH are limited and primarily focus on addressing underlying risk factors such as weight management and blood sugar control.

Semaglutide has been shown to be effective in managing obesity and improving glycemic control, but its impact on liver health specifically is still under investigation. This new study seeks to expand the understanding of semaglutide’s potential benefits when combined with CS060380—a peptide being developed by Cascade Pharmaceuticals, Inc.

Key Details

The study, titled "A Study of CS060380 Tablets in Patients With MASH and Obesity," is recruiting participants across multiple sites. Researchers will monitor the effects of a combination therapy involving semaglutide and CS060380 compared to those who receive placebo treatments.

This trial is crucial as it targets two major public health concerns: obesity and liver disease. The research aims to determine if the combined use of these peptides can improve outcomes for patients with MASH, offering hope to millions worldwide who suffer from this debilitating condition.

The study duration spans up to 54 weeks, providing ample time to assess long-term benefits and safety profiles associated with the new investigational drug CS060380. Participants will be closely monitored throughout the trial period to gather comprehensive data on the effectiveness of this novel treatment approach.

Key Takeaways

  • Novel Combination Therapy: The study explores the potential synergy between semaglutide and CS060380 for treating MASH.
  • Patient Recruitment: Researchers are actively recruiting adults who suffer from both obesity and metabolic dysfunction-associated steatohepatitis.
  • Long-term Monitoring: Participants will be followed for up to 54 weeks, ensuring detailed insights into the safety and efficacy of the treatment over time.
  • Potential for Breakthroughs: This research could pave the way for new therapeutic options in managing liver health issues linked with obesity.

What This Means

For the peptide community, this study represents a significant step forward in exploring innovative treatments for complex metabolic disorders. The combination therapy approach offers promising possibilities for improving patient outcomes and quality of life. If successful, CS060380 could become an important addition to the toolkit of medical professionals dealing with MASH and obesity.

---

Source: ClinicalTrials.gov — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

Nota do Editor

Esta análise foi gerada usando ferramentas de inteligência artificial e revisada pela equipe editorial da Peptide Contacts. Embora busquemos a precisão, o conteúdo gerado por inteligência artificial pode conter erros ou omissões. Encorajamos os leitores a revisar o fonte original para detalhes completos, metodologia e dados.

A Peptide Contacts fornece resumos de pesquisa curados para fins informativos apenas. Este conteúdo não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.

Comments

Sign in to join the discussion

Este artigo foi gerado usando inteligência artificial e pode conter inaccuracy. É fornecido para fins informativos apenas e não constitui conselhos médicos. Sempre verifique as informações com a fonte original e consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.